FDA Nod for Adjuvant Pembrolizumab in Kidney Cancer FDA Nod for Adjuvant Pembrolizumab in Kidney Cancer

This is the first immunotherapy to be approved for adjuvant use in intermediate- or high-risk patients with renal cell carcinoma after surgery.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news